RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Edwards Lifesciences ROE 2024

Edwards Lifesciences ROE

0.21

Edwards Lifesciences Dividend yield

Ticker

EW

ISIN

US28176E1082

WKN

936853

In 2024, Edwards Lifesciences's return on equity (ROE) was 0.21, a -19.54% increase from the 0.26 ROE in the previous year.

Edwards Lifesciences Aktienanalyse

What does Edwards Lifesciences do?

Edwards Lifesciences Corp is a globally operating company in the field of medical technology, specializing in the development, production, and distribution of products for the treatment of heart diseases and critical illnesses. The company was founded in California in 1958 and is now one of the leading companies in the field of modern heart valve technology. The history of Edwards Lifesciences begins with its founding by Miles "Lowell" Edwards and his longtime employee Dr. Albert Starr. They recognized the need for a less invasive and more effective alternative to heart valves than the existing surgical methods. They received their first patent in 1960 and performed their first successful heart valve operation on a sheep in the same year. The first surgeries on humans took place in 1962. Edwards Lifesciences quickly expanded in the US and internationally. The business model of Edwards Lifesciences focuses on three business areas: "Transcatheter Heart Valve Systems," "Surgical Heart Valve Therapy," and "Critical Care." Each area is focused on a specific range of products and is supported by its own team of professionals. The "Transcatheter Heart Valve Systems" area has become the most important division of Edwards Lifesciences. This novel technology enables the implantation of an artificial heart valve system through minimally invasive surgical methods, without the need for an open procedure. The system consists of a foldable heart valve made of animal tissue or artificial material, which is inserted into the damaged heart through a catheter. This method is applicable to a wide range of patients and has become an important tool in the treatment of heart diseases. The "Surgical Heart Valve Therapy" business area includes implantable mechanical and biological heart valves for open surgical procedures. Edwards Lifesciences develops innovative products to meet the needs of surgical patients and doctors. The third business area, "Critical Care," offers instruments and technologies for the critical medical care of patients in intensive care units and emergency departments. The company manufactures collagen matrix products for wound care, catheter monitoring systems, and patient monitoring devices to detect potential life-threatening complications early. Over the years, Edwards Lifesciences has introduced numerous innovative products to the market that are used in medical practice. The Edwards SAPIEN Transcatheter Heart Valve System was approved in Europe in 2011 and in the US in 2012 and has since improved the lives of tens of thousands of patients. With new technologies such as the Edwards SAPIEN 3 and SAPIEN 3 Ultra platforms, the company is constantly striving to increase the effectiveness and safety of heart disease treatment. Edwards Lifesciences is headquartered in Irvine, California, and is a multinational company with locations in North America, Europe, India, and Asia. The company currently employs approximately 14,000 people worldwide and is an important pillar of the medical community. Answer: Edwards Lifesciences Corp is a global medical technology company specializing in the development, production, and distribution of products for the treatment of heart diseases and critical illnesses. It is a leader in modern heart valve technology. Edwards Lifesciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Edwards Lifesciences's Return on Equity (ROE)

Edwards Lifesciences's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Edwards Lifesciences's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Edwards Lifesciences's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Edwards Lifesciences’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Edwards Lifesciences Stock

What is the ROE (Return on Equity) of Edwards Lifesciences this year?

The ROE of Edwards Lifesciences this year is 0.21 undefined.

How has the Return on Equity (ROE) of Edwards Lifesciences developed compared to the previous year?

The ROE of Edwards Lifesciences has increased by -19.54% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Edwards Lifesciences?

A high ROE indicates that Edwards Lifesciences generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Edwards Lifesciences?

A low ROE can indicate that Edwards Lifesciences is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Edwards Lifesciences affect the company?

A change in ROE (Return on Equity) of Edwards Lifesciences can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Edwards Lifesciences?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Edwards Lifesciences?

Some factors that can influence Edwards Lifesciences's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Edwards Lifesciences pay?

Over the past 12 months, Edwards Lifesciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Edwards Lifesciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Edwards Lifesciences?

The current dividend yield of Edwards Lifesciences is .

When does Edwards Lifesciences pay dividends?

Edwards Lifesciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Edwards Lifesciences?

Edwards Lifesciences paid dividends every year for the past 0 years.

What is the dividend of Edwards Lifesciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Edwards Lifesciences located?

Edwards Lifesciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Edwards Lifesciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Edwards Lifesciences from 5/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/16/2024.

When did Edwards Lifesciences pay the last dividend?

The last dividend was paid out on 5/16/2024.

What was the dividend of Edwards Lifesciences in the year 2023?

In the year 2023, Edwards Lifesciences distributed 0 USD as dividends.

In which currency does Edwards Lifesciences pay out the dividend?

The dividends of Edwards Lifesciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Edwards Lifesciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Edwards Lifesciences

Our stock analysis for Edwards Lifesciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Edwards Lifesciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.